BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months
Biotech catalysts in 2024-01
169 industry Phase 2/3 trial readout(s) and 23 FDA decision event(s). Readouts include completed (ACTUAL) and still-estimated primary completion dates in this month, any status.
FDA decision events
| Date | Event | Status | Company | Drug | Source |
|---|---|---|---|---|---|
| 2024-01-04 | Complete response letter | approved since | Astellas Pharma US, Inc. | IMAB362 | CRL 2024-01-04: Astellas Pharma US, Inc. BLA 761365 (IMAB362) |
| 2024-01-05 | FDA approval | approved | LNHC | ZELSUVMI | Approved 2024-01-05: ZELSUVMI (NDA217424 ORIG1) |
| 2024-01-05 | FDA approval | approved | FRESENIUS KABI USA | IDACIO | Approved 2024-01-05: IDACIO (BLA761255 ORIG2) |
| 2024-01-08 | FDA approval | approved | PROVEPHARM SAS | PROVAYBLUE | Approved 2024-01-08: PROVAYBLUE (NDA204630 SUPPL21) |
| 2024-01-12 | Complete response letter | complete response | SQ Innovation, Inc. | furosemide injection | CRL 2024-01-12: SQ Innovation, Inc. NDA 217294 (furosemide injection) |
| 2024-01-12 | FDA approval | approved | MERCK SHARP DOHME MRK | KEYTRUDA | Approved 2024-01-12: KEYTRUDA (BLA125514 SUPPL147) |
| 2024-01-12 | FDA approval | approved | REGENERON PHARMACEUTICALS REGN | DUPIXENT | Approved 2024-01-12: DUPIXENT (BLA761055 SUPPL55) |
| 2024-01-17 | Complete response letter | complete response | BendaRx USA Corporation | one or more listed drugs (LDs) for approval, you must establish that such reliance is scientifically appropriate | CRL 2024-01-17: BendaRx USA Corporation NDA 215291 (one or more listed drugs (LDs) for approval, you must establish that such reliance is scientifically appropriate) |
| 2024-01-18 | FDA approval | approved | NOVARTIS NVS | PIQRAY | Approved 2024-01-18: PIQRAY (NDA212526 SUPPL9) |
| 2024-01-19 | Complete response letter | approved since | Akeso Biopharma Co., Ltd. | CRL 2024-01-19: Akeso Biopharma Co., Ltd. BLA 761258 | |
| 2024-01-19 | FDA approval | approved | JANSSEN BIOTECH | BALVERSA | Approved 2024-01-19: BALVERSA (NDA212018 SUPPL8) |
| 2024-01-19 | FDA approval | approved | JANSSEN BIOTECH | BALVERSA | Approved 2024-01-19: BALVERSA (NDA212018 SUPPL9) |
| 2024-01-23 | Complete response letter | complete response | Hikma Pharmaceuticals USA, Inc. | phenobarbital sodium injection | CRL 2024-01-23: Hikma Pharmaceuticals USA, Inc. NDA 218258 (phenobarbital sodium injection) |
| 2024-01-23 | FDA approval | approved | HERON THERAPS INC | ZYNRELEF KIT | Approved 2024-01-23: ZYNRELEF KIT (NDA211988 SUPPL13) |
| 2024-01-24 | FDA approval | approved | ASTRAZENECA AZN | KOSELUGO | Approved 2024-01-24: KOSELUGO (NDA213756 SUPPL4) |
| 2024-01-25 | Complete response letter | complete response | Defender Pharmaceuticals, Inc | CRL 2024-01-25: Defender Pharmaceuticals, Inc NDA 214315 | |
| 2024-01-25 | Complete response letter | complete response | AFT Pharmaceuticals Ltd | sirolimus | CRL 2024-01-25: AFT Pharmaceuticals Ltd NDA 218528 (sirolimus cream) |
| 2024-01-25 | FDA approval | approved | MERCK SHARP DOHME MRK | KEYTRUDA | Approved 2024-01-25: KEYTRUDA (BLA125514 SUPPL124) |
| 2024-01-25 | FDA approval | approved | REGENERON PHARMACEUTICALS REGN | DUPIXENT | Approved 2024-01-25: DUPIXENT (BLA761055 SUPPL57) |
| 2024-01-26 | FDA approval | approved | BRISTOL MYERS SQUIBB BMY | OPDIVO | Approved 2024-01-26: OPDIVO (BLA125554 SUPPL122) |
| 2024-01-26 | FDA approval | approved | ABBVIE ABBV | AVYCAZ | Approved 2024-01-26: AVYCAZ (NDA206494 SUPPL12) |
| 2024-01-30 | Complete response letter | complete response | Accord Healthcare Inc. | Epinephrine | CRL 2024-01-30: Accord Healthcare Inc. NDA 218470 (Epinephrine injection) |
| 2024-01-31 | FDA approval | approved | ASTRAZENECA AZN | TAGRISSO | Approved 2024-01-31: TAGRISSO (NDA208065 SUPPL29) |
Trial readouts
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2024-01 est. | P3 | Mentor Worldwide, LLC | NCT00981266 Spectra Breast Implant Study | Augmentation; Augmentation Revision; General Breast Enlargement; Post-lactational Involution; Asymme | withdrawn | |
| 2024-01 est. | P1/P2 | Conjupro Biotherapeutics, Inc. | NCT03553914 PLM60 for Peripheral T Cell Lymphoma (PTCL) | Peripheral T Cell Lymphoma | withdrawn | |
| 2024-01 est. | P2 | Sorrento Therapeutics, Inc. | NCT03999658 A Study of STI-3031 (an Anti-PD-L1 Antibody) in Patients With Selected Relapsed/Refractory Malignancies | Peripheral T Cell Lymphoma; Diffuse Large B Cell Lymphoma; Biliary Tract Cancer; Extranodal NK T Cel | withdrawn | |
| 2024-01 est. | P1/P2 | Ascentage Pharma Group Inc. AAPG | NCT04674514 APG-2575 Monotherapy or in Combination With Lenalidomide/DXMS in Subjects With Relapsed or Refractory Multiple Myeloma | Multiple Myeloma | unknown | 48 |
| 2024-01 est. | P2 | Frame Pharmaceuticals B.V. | NCT04998474 FRAME-001 Personalized Vaccine in NSCLC | Non Small Cell Lung Cancer | unknown | 15 |
| 2024-01 est. | P2/P3 | Alachua Government Services, Inc. | NCT05142527 Study to Evaluate the Safety and Efficacy of a Monoclonal Antibody Cocktail for the Prevention of COVID-19 | COVID-19 | withdrawn | |
| 2024-01 est. | P2 | Saol Therapeutics Inc | NCT05470608 Phase II Study to Assess Safety and Efficacy of SL-1002 for Osteoarthritic Knee Pain | Osteoarthritis, Knee Pain | unknown | 132 |
| 2024-01 est. | P2 | Soleno Therapeutics, Inc. | NCT05532020 An Open-Label Study of Diazoxide Choline in Patients With Genetic Obesities | SH2B1 Deficiency Obesity; Obesity Associated With PCSK1 Mutation (rs6232 Variant); SIM1 Deficiency O | withdrawn | |
| 2024-01 est. | P2 | Telios Pharma, Inc. | NCT06153342 A Study of TL-925 for the Treatment of Allergic Conjunctivitis | Allergic Conjunctivitis | unknown | 70 |
| 2024-01-01 | P3 | AbbVie ABBV | NCT02814916 Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections in Children, Known or Suspected to be Caused by Susceptible Gram-positive Or | Methicillin-Resistant Staphylococcus Aureus; Bacterial Infections; Staphylococcal Skin Infections | completed | 199 |
| 2024-01-01 est. | P2 | Qilu Pharmaceutical Co., Ltd. | NCT05329025 A Study of QL1706 Combined With Chemotherapy in Advanced Non-small Cell Lung Cancer | Non-small-cell Lung Cancer | unknown | 100 |
| 2024-01-01 est. | P2 | Mabwell (Shanghai) Bioscience Co., Ltd. | NCT05440045 A Clinical Study of 6MW3211 in Patients With Renal Cancer | Advanced Clear Cell Renal Cell Carcinoma | unknown | 30 |
| 2024-01-01 | P2 | Pfizer PFE | NCT05886777 A Study to Learn About Two or More Vaccines That Are Put Together as One Shot Against Infectious Lung Illnesses, Including COVID-19 and Respiratory Syncytial Vi | Healthy Participants | completed | 1142 |
| 2024-01-01 est. | P1/P2 | Aptevo Therapeutics APVO | NCT05934539 ALG.APV-527 First-in-human Study | Solid Tumor | unknown | 56 |
| 2024-01-02 | P2/P3 | Eli Lilly and Company LLY | NCT03706365 A Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib (LY2835219) in Participants With Prostate Cancer | Prostate Cancer | active not recruiting | 393 |
| 2024-01-02 | P3 | VectivBio AG | NCT04627025 Trial to Evaluate Efficacy and Safety of Apraglutide in SBS-IF | Short Bowel Syndrome | completed | 164 |
| 2024-01-02 | P2 | CSL Behring | NCT05130970 Garadacimab Safety, Pharmacokinetics, and Pharmacodynamics in Idiopathic Pulmonary Fibrosis | Idiopathic Pulmonary Fibrosis | completed | 81 |
| 2024-01-02 | P2 | Chipscreen Biosciences, Ltd. | NCT05193916 A Phase II Clinical Trial of Chiglitazar for NASH | NASH | completed | 104 |
| 2024-01-02 | P2 | Ventyx Biosciences, Inc | NCT05715125 VTX958 Versus Placebo for the Treatment of Active Psoriatic Arthritis (Tranquility-PsA) | Psoriatic Arthritis | terminated | 205 |
| 2024-01-03 | P3 | AstraZeneca AZN | NCT04075292 Study of Acalabrutinib Versus Chlorambucil Plus Rituximab in Adult Subjects With Previously Untreated Chronic Lymphocytic Leukemia | Untreated Chronic Lymphocytic Leukemia | active not recruiting | 155 |
| 2024-01-03 | P2 | AbbVie ABBV | NCT04451772 A Study of the Safety of Oral Elsubrutinib Capsules and Oral Upadacitinib Tablets Given Alone or in Combination (ABBV-599) for Adult Participants With Moderatel | Systemic Lupus Erythematosus (SLE) | completed | 185 |
| 2024-01-03 | P3 | Takeda TAK | NCT04974749 A Study of REPLAGAL® in Treatment-naive Chinese Participants With Fabry Disease | Fabry Disease | completed | 20 |
| 2024-01-03 | P2 | Seagen Inc. | NCT04993677 A Study of SEA-CD40 Given With Other Drugs in Cancers | Melanoma; Carcinoma, Non-Small- Cell Lung | completed | 77 |
| 2024-01-03 | P3 | Janssen Research & Development, LLC | NCT05388669 A Study of Lazertinib With Subcutaneous Amivantamab Compared With Intravenous Amivantamab in Participants With Epidermal Growth Factor Receptor (EGFR)-Mutated A | Advanced or Metastatic Non-small Cell Lung Cancer | active not recruiting | 418 |
| 2024-01-03 | P2 | Bayer | NCT05656911 A Study to Learn How Well the Study Treatment Zabedosertib (BAY1834845) Works and How Safe it is Compared to Placebo in Adult Participants With Moderate-to-seve | Atopic Dermatitis | completed | 77 |
| 2024-01-04 | P2/P3 | Merck Sharp & Dohme LLC MRK | NCT04732221 A Study of the Efficacy and Safety of Frespaciguat (MK-5475) in Participants With Pulmonary Arterial Hypertension (INSIGNIA-PAH: Phase 2/3 Study of an Inhaled s | Pulmonary Arterial Hypertension; Hypertension, Pulmonary | completed | 168 |
| 2024-01-04 | P2/P3 | Galderma R&D | NCT05075408 To Evaluate the Efficacy and Safety of Nemolizumab for 12 Weeks in Participants With Chronic Kidney Disease With Associated Moderate to Severe Pruritus | Chronic Kidney Disease Associated Moderate to Severe Pruritus | completed | 258 |
| 2024-01-04 | P3 | Bayer | NCT05147662 A Study to Learn How Safe the Study Treatment BAY94-9027 is and How it Affects the Body in Previously Treated Children Aged 7 to Less Than 12 Years With Severe | Treatment of Bleeding; Prophylaxis of Bleeding; Hemophilia A; Children | completed | 36 |
| 2024-01-04 | P2 | Amgen AMGN | NCT05540665 Study of Daxdilimab (HZN-7734) in Participants With Active Proliferative Lupus Nephritis (LN) | Lupus Nephritis | terminated | 19 |
| 2024-01-04 | P2 | GEN İlaç ve Sağlık Ürünleri A.Ş. | NCT05706870 Phase II Study Evaluating the Clinical Efficacy and Safety of GN-037 in Plaque Psoriasis | Psoriasis | completed | 190 |
| 2024-01-04 | P3 | Faes Farma, S.A. | NCT05788497 Efficacy and Safety of Hemorrane Plus Versus Hemorrane and Versus Placebo in Patients With Uncomplicated Haemorrhoids | Haemorrhoids Without Complication | terminated | 21 |
| 2024-01-04 | P2 | Jiangsu Hansoh Pharmaceutical Co., Ltd. | NCT06118008 A Study of HS-20094 in T2DM Participants | Type 2 Diabetes | completed | 54 |
| 2024-01-04 | P3 | Taejoon Pharmaceutical Co., Ltd. | NCT06287606 A Phase 3 Clinical Trials for Bowel Preparation for Colonoscopy | Bowel Preparation | completed | 161 |
| 2024-01-05 | P1/P2 | Bristol-Myers Squibb BMY | NCT03195478 A Study of Nivolumab in Combination With Ipilimumab in Chinese Participants With Previously Treated Advanced or Recurrent Solid Tumors | Solid Tumor | completed | 37 |
| 2024-01-05 | P3 | AstraZeneca AZN | NCT03521154 A Global Study to Assess the Effects of Osimertinib Following Chemoradiation in Patients With Stage III Unresectable Non-small Cell Lung Cancer (LAURA) | Non Small Cell Lung Cancer (Stage III) | active not recruiting | 216 |
| 2024-01-05 | P2 | Pfizer PFE | NCT04440176 A Trial to Describe the Safety and Immunogenicity of MenABCWY When Administered on 2 Schedules | Meningococcal Vaccine | completed | 309 |
| 2024-01-05 | P1/P2 | Eirion Therapeutics Inc. | NCT05565950 AI-09 In Subjects With Glabellar Lines, GL-101 | Glabellar Frown Lines | completed | 96 |
| 2024-01-05 | P3 | ModernaTX, Inc. | NCT05566639 A Study of mRNA-1010 Seasonal Influenza Vaccine in Adults 50 Years Old and Older | Seasonal Influenza | completed | 22502 |
| 2024-01-05 | P3 | Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. | NCT05642078 Phase Ⅲ Clinical Study of Quadrivalent Influenza Virus Split Vaccine | Prevention of Influenza | completed | 2550 |
| 2024-01-05 | P3 | AO GENERIUM | NCT06475508 Comparison of Complarate® (Tocilizumab Biosimilar) and Actemra® in Patients With Rheumatoid Arthritis | Rheumatoid Arthritis | completed | 465 |
| 2024-01-06 | P2 | Bristol-Myers Squibb BMY | NCT05556265 A Study to Evaluate Efficacy and Safety of Deucravacitinib in Participants With Alopecia Areata | Alopecia Areata | terminated | 94 |
| 2024-01-07 | P3 | Shionogi | NCT05305547 A Study to Compare S-217622 With Placebo in Non-Hospitalized Participants With COVID-19 | SARS-CoV-2 Infection | completed | 2093 |
| 2024-01-08 | P1/P2 | Handok Inc. | NCT04492033 A Study of CTX-009 (ABL001) in Combination With Irinotecan or Paclitaxel in Advanced or Metastatic Solid Tumor Patients | P1b: Advanced Solid Tumors; P2: Biliary Tract Cancer | terminated | 41 |
| 2024-01-08 est. | P2 | Takeda TAK | NCT04985656 A Study of Pevonedistat Combined With Decitabine and Cedazuridine in Adults With Higher-risk Myelodysplastic Syndromes | Myelodysplastic Syndromes (MDS) | withdrawn | |
| 2024-01-08 | P1/P2 | T-knife GmbH | NCT05430555 A Phase 1/ 2, First-in-Human, Open-Label, Accelerated-Titration, Two-Part Clinical Trial of TK-8001 in Patients With HLA-A*02:01 Genotype and Advanced-Stage/ Me | Advanced Solid Tumors | terminated | 23 |
| 2024-01-09 | P2 | Medipost Co Ltd. | NCT03392467 PNEUMOSTEM for the Prevention and Treatment of Severe BPD in Premature Infants | Severe Bronchopulmonary Dysplasia | completed | 60 |
| 2024-01-09 | P3 | Novo Nordisk A/S NVO | NCT03819153 A Research Study to See How Semaglutide Works Compared to Placebo in People With Type 2 Diabetes and Chronic Kidney Disease | Diabetes Mellitus, Type 2 | completed | 3533 |
| 2024-01-09 | P1/P2 | Orion Corporation, Orion Pharma ORN | NCT03878823 Safety and Pharmacokinetics of ODM-209 | Prostate Cancer Metastatic; Advanced Breast Cancer; Castration-resistant Prostate Cancer; Metastatic | completed | 38 |
| 2024-01-09 | P1/P2 | Beijing Mabworks Biotech Co., Ltd. | NCT04110301 MIL62 Plus Lenalidomide for Patients With Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma (FL and MZL) | Follicular Lymphoma and Marginal Zone Lymphoma | unknown | 53 |
| 2024-01-09 | P2 | Beijing InnoCare Pharma Tech Co., Ltd. | NCT04440059 A Study of ICP-022 in the Treatment of Recurrent or Refractory Waldenstrom Macroglobulinemia | Waldenstrom's Macroglobulinemia Recurrent; Waldenstrom's Macroglobulinemia Refractory | completed | 47 |
| 2024-01-09 | P3 | Veru Inc. VERU | NCT04869943 Efficacy Evaluation of Enobosarm Monotherapy in Treatment of AR+/ER+/HER2- Metastatic Breast Cancer | Metastatic Breast Cancer | terminated | 52 |
| 2024-01-09 | P2/P3 | Hipra Scientific, S.L.U | NCT05303402 A Phase IIb/III Clinical Trial to Assess Safety and Immunogenicity of a COVID-19 Vaccine Booster Dose in Immunosupressed Adults. | SARS CoV 2 Infection | completed | 240 |
| 2024-01-09 | P2 | Alexion Pharmaceuticals, Inc. | NCT05565092 Safety, Efficacy, Pharmacokinetic, and Pharmacodynamic Study of ALXN1820 in Adult Participants With Sickle Cell Disease | Sickle Cell Disease (SCD) | terminated | 2 |
| 2024-01-09 | P2 | Kiora Pharmaceuticals, Inc. KPRX | NCT05629364 A Multi-Centre, Randomised, Controlled, Masked Phase 2 Study of the Safety and Efficacy of KIO-101 Ophthalmic Solution, Versus Vehicle Control in the Treatment | Dry Eye Disease | terminated | 4 |
| 2024-01-09 | P3 | Ferrer Internacional S.A. | NCT05866926 Study to Investigate the Long-term Safety of FAB122 in Patients With Amyotrophic Lateral Sclerosis | Amyotrophic Lateral Sclerosis | terminated | 201 |
| 2024-01-10 | P3 | Techfields Pharma Co. Ltd | NCT03081806 A Study to Evaluate the Efficacy and Safety of X0002 Spray in Subjects With Osteoarthritis Knee Pain | Pain Associated With Osteoarthritis of the Knee | completed | 399 |
| 2024-01-10 | P1/P2 | Ability Pharmaceuticals SL | NCT04431258 ABTL0812 in Combination With FOLFIRINOX for First-line Treatment of Metastatic Pancreatic Study | Pancreatic Cancer | completed | 150 |
| 2024-01-10 | P2 | Boehringer Ingelheim | NCT04521478 A Study to Test the Effect of Different Doses of BI 1358894 and Quetiapine in People With Depression | Depressive Disorder, Major | completed | 389 |
| 2024-01-10 | P2 | Annexon, Inc. ANNX | NCT04569435 Study of ANX005 in Adults With Amyotrophic Lateral Sclerosis (ALS) | Amyotrophic Lateral Sclerosis | completed | 17 |
| 2024-01-10 | P2 | Ionis Pharmaceuticals, Inc. IONS | NCT04932512 A Study to Assess the Safety, Efficacy, and Pharmacokinetics of Multiple Doses of ION224 | Steatohepatitis, Nonalcoholic | completed | 160 |
| 2024-01-10 | P2 | Neurocrine Biosciences NBIX | NCT05203341 Study to Assess the Efficacy and Safety of NBI-1065845 in Adults With Major Depressive Disorder (MDD) | Major Depressive Disorder | completed | 183 |
| 2024-01-10 | P3 | Chong Kun Dang Pharmaceutical | NCT05566028 The Efficacy and Safety of D745 Added to D150 Plus D759 Therapy in Patients with Type 2 Diabetes | Type 2 Diabetes | completed | 172 |
| 2024-01-11 | P2 | Ultimovacs ASA | NCT04382664 UV1 Vaccination Plus Nivolumab and Ipilimumab in Treatment of Melanoma | Malignant Melanoma | completed | 156 |
| 2024-01-11 | P2 | Bristol-Myers Squibb BMY | NCT04623775 A Study of Relatlimab Plus Nivolumab in Combination With Chemotherapy vs. Nivolumab in Combination With Chemotherapy as First Line Treatment for Participants Wi | Non-small Cell Lung Cancer; Recurrent Non-small Cell Lung Cancer; Metastatic Non-small Cell Lung Can | completed | 468 |
| 2024-01-11 | P3 | Celgene | NCT04753697 A Study to Evaluate the Efficacy and Safety of CC-93538 in Adult and Adolescent Participants With Eosinophilic Esophagitis | Eosinophilic Esophagitis | completed | 430 |
| 2024-01-11 est. | P3 | Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd | NCT05156528 Efficacy, Immunogenicity and Safety of S. Flexneriza-S. Sonnei Bivalent Conjugate Vaccine in Volunteers Aged From 6 Months to 5 Years | Dysentery; Shigellosis | unknown | 21000 |
| 2024-01-11 | P3 | Eli Lilly and Company LLY | NCT05369403 A Study of Lebrikizumab (LY3650150) in Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis Previously Treated With Dupilumab | Atopic Dermatitis | completed | 86 |
| 2024-01-11 | P2 | Silence Therapeutics plc SLN | NCT05537571 Evaluate SLN360 in Participants With Elevated Lipoprotein(a) at High Risk of Atherosclerotic Cardiovascular Disease Events | Cardiovascular Diseases; Atherosclerosis; Lipoprotein(a) | completed | 180 |
| 2024-01-12 | P3 | Omeros Corporation OMER | NCT03608033 Study of the Safety and Efficacy of OMS721 in Patients With Immunoglobulin A (IgA) Nephropathy | IgA Nephropathy | terminated | 360 |
| 2024-01-12 | P1/P2 | Menarini Group | NCT04495621 MEN1611 With Cetuximab in Metastatic Colorectal Cancer (C-PRECISE-01) | Metastatic Colorectal Cancer | completed | 29 |
| 2024-01-12 | P2 | Enlivex Therapeutics Ltd. ENLV | NCT04612413 A Phase 2 Study Evaluating Efficacy, Safety and Tolerability of Different Doses and Regimens of Allocetra-OTS for the Treatment of Organ Failure in Adult Sepsis | Sepsis; Community-acquired Pneumonia; Urinary Tract Infections; Cholecystitis, Acute; Cholangitis Ac | completed | 148 |
| 2024-01-12 | P2 | Hangzhou Hanx Biopharmaceuticals, Ltd. | NCT04886271 Recombinant Humanized Anti-CD47 / PD-1 Bifunctional Antibody HX009 Injection in the Treatment of Advanced Solid Tumors | Advanced Solid Tumor | completed | 20 |
| 2024-01-12 | P3 | Organon and Co OGN | NCT05264506 Contraceptive Efficacy and Safety of NOMAC-E2 Combined Oral Contraceptive | Contraception | terminated | 3055 |
| 2024-01-12 | P2 | Suzhou Raymon Pharmaceuticals Company, Ltd. | NCT05794204 RMP-A03 Ocular Suspension in Patients With Pterygium | Pterygium | completed | 77 |
| 2024-01-15 | P3 | AstraZeneca AZN | NCT03703297 Study of Durvalumab + Tremelimumab, Durvalumab, and Placebo in Limited Stage Small-Cell Lung Cancer in Patients Who Have Not Progressed Following Concurrent Che | Small Cell Lung Cancer | active not recruiting | 730 |
| 2024-01-15 | P2/P3 | MacroGenics MGNX | NCT04082364 Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ Cancer | Gastric Cancer; Gastroesophageal Junction Cancer; HER2-positive Gastric Cancer | completed | 82 |
| 2024-01-15 | P2 | Novartis Pharmaceuticals NVS | NCT04129528 Study of Safety and Efficacy of CFZ533 in Type 1 Diabetes Pediatric and Young Adult Subjects | Type 1 Diabetes Mellitus | completed | 44 |
| 2024-01-15 | P2 | Allay Therapeutics, Inc. | NCT05260008 Study Assessing Pain Relief After Replacement of the Knee | Acute Postoperative Pain | terminated | 112 |
| 2024-01-15 | P3 | EuBiologics Co.,Ltd | NCT05603052 A Phase III of COVID-19 Vaccine EuCorVac-19 in Healthy Adults Aged 18 Years and Older | COVID-19 | completed | 2852 |
| 2024-01-15 | P2 | Sinocelltech Ltd. | NCT05652543 A PhaseⅡ Study to Evaluate the Safety & Immunogenicity of SARS-CoV-2 Alpha/Beta/Delta/Omicron Variants COVID-19 Vaccine | COVID-19 Pandemic | completed | 518 |
| 2024-01-15 | P3 | Medprin Regenerative Medical Technologies Co., Ltd. | NCT07764055 A Trial of Absorbable Regenerated Oxidized Cellulose for Surgical Hemostasis) | Surgical Bleeding; Hemorrhage; Oxidized Regenerated Cellulose | completed | 288 |
| 2024-01-16 | P3 | Actelion | NCT03232073 Long-term Extension to Study AC-058B301 to Investigate Safety, Tolerability and Disease Control of Ponesimod 20 mg in Patients With Relapsing Multiple Sclerosis | Multiple Sclerosis | completed | 877 |
| 2024-01-16 | P1/P2 | Barinthus Biotherapeutics | NCT04607850 Prime-boost Vaccine Study in Women With Low-grade Cervical HPV Lesions | HPV Infection; CIN1 | completed | 108 |
| 2024-01-16 | P1/P2 | atai Therapeutics, Inc. | NCT05029401 A Study of Oral Ibogaine in Opioid Withdrawal | Opiate Withdrawal Syndrome | completed | 116 |
| 2024-01-16 | P3 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | NCT05375461 TQB3616 Capsules Plus Fulvestrant Compared to Placebo Plus Fulvestrant in Previously Treated Breast Cancer in Clinical Trail | HR-positive,HER2-negative in Advanced Breast Cancer | completed | 293 |
| 2024-01-16 | P2/P3 | Novavax NVAX | NCT05468736 Study to Evaluate Safety and Immunogenicity of COVID-19 Vaccine in Children 6 Months to < 12 Years | COVID-19 | completed | 3600 |
| 2024-01-16 | P2 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | NCT05987371 A Clinical Trial of TQC3721 Suspension for Inhalation in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease. | Chronic Obstructive Pulmonary Disease | completed | 75 |
| 2024-01-17 | P2 | Tanabe Pharma America, Inc. | NCT04440592 Study to Evaluate Efficacy, Safety, and Tolerability of MT-7117 in Subjects With Diffuse Cutaneous Systemic Sclerosis | Diffuse Cutaneous Systemic Sclerosis | completed | 76 |
| 2024-01-17 | P2 | Supernus Pharmaceuticals, Inc. SUPN | NCT05318937 A Study to Evaluate the Effects of SAGE-718 in Participants With Parkinson's Disease Cognitive Impairment | Parkinson Disease; Cognitive Dysfunction | completed | 86 |
| 2024-01-17 | P3 | Sobi, Inc. | NCT05369208 Evaluation of Avatrombopag for the Treatment of Thrombocytopenia in Japanese Adults With Chronic ITP | Immune Thrombocytopenia | completed | 19 |
| 2024-01-17 | P2 | Suzhou Alphamab Co., Ltd. | NCT05421429 KN057 Multiple Dose Study in Moderately Severe to Severe Hemophilia | Hemophilia | completed | 24 |
| 2024-01-17 | P2/P3 | Neurocentria, Inc. | NCT05683249 Study to Evaluate NRCT-101SR in Adult Attention Deficit Hyperactivity Disorder (ADHD) | ADHD | completed | 223 |
| 2024-01-18 | P3 | Pfizer PFE | NCT04218084 Study to Evaluate the Effect of GBT440 on TCD in Pediatrics With Sickle Cell Disease | Sickle Cell Disease | terminated | 236 |
| 2024-01-18 | P3 | Biogen BIIB | NCT05265728 A Study to Evaluate Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of Natalizumab (BG00002) Administered Subcutaneously to Japanese | Multiple Sclerosis, Relapsing-Remitting | terminated | 21 |
| 2024-01-18 | P3 | Pfizer PFE | NCT05399485 Efficacy and Safety Study of Rimegepant for Migraine Prevention in Japanese Subjects (Japan Only) | Migraine | completed | 496 |
| 2024-01-18 | P2 | Mylan Pharmaceuticals Inc | NCT06048536 Dose-finding Study of MR-130A-01 Contraceptive Transdermal Patch | Contraception | completed | 168 |
| 2024-01-19 | P1/P2 | BioNTech SE BNTX | NCT04101357 Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT411 | Solid Tumor; Extensive-stage Small Cell Lung Cancer | terminated | 54 |
| 2024-01-19 | P2 | Regeneron Pharmaceuticals REGN | NCT04633278 CMP-001 in Combination With Pembrolizumab in Subjects With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma | Squamous Cell Carcinoma of Head and Neck | terminated | 24 |
| 2024-01-19 | P3 | Amylyx Pharmaceuticals Inc. AMLX | NCT05021536 Phase III Trial of AMX0035 for Amyotrophic Lateral Sclerosis Treatment | Amyotrophic Lateral Sclerosis | unknown | 664 |
| 2024-01-19 | P2 | Microbion Corporation | NCT05174806 Multi-center Study to Assess Safety, Tolerability and Efficacy of Topical Pravibismane in Moderate DFI Patients | Diabetic Foot Infection; Diabetic Foot | completed | 47 |
| 2024-01-19 | P3 | Pfizer PFE | NCT05399459 Efficacy and Safety Study of Rimegepant for the Acute Treatment of Migraine in Japanese Subjects (Japan Only) | Migraine | completed | 897 |
| 2024-01-19 | P1/P2 | Sanofi Pasteur, a Sanofi Company SNY | NCT05553301 Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5407 in Adult Participants18 Years of Age and Older | Influenza Immunization | completed | 560 |
| 2024-01-19 | P2/P3 | HilleVax | NCT05836012 Safety and Immunogenicity of HIL-214 With Routine Pediatric Vaccines | Gastroenteritis | completed | 329 |
| 2024-01-19 | P2 | Changchun GeneScience Pharmaceutical Co., Ltd. | NCT05936281 A Study of the Efficacy of Genakumab in Prevention of Acute Flares in Gout Patients Initiating Urate-lowering TherapyUrate-lowering (GenSci048-202) | Gout; Gout Initiating Urate-loweringUrate-lowering Therapy | completed | 165 |
| 2024-01-20 | P3 | Crinetics Pharmaceuticals Inc. | NCT05192382 A Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (PATHFNDR-2) | Acromegaly | terminated | 111 |
| 2024-01-20 est. | P2 | Shanghai Kechow Pharma, Inc. | NCT05233332 Study of HL-085 and Vemurafinib in Metastatic Colorectal Cancer (mCRC) | CRC | unknown | 186 |
| 2024-01-21 | P2 | Shanghai Ming Ju Biotechnology Co., Ltd. | NCT06093841 Relmacabtagene Autoleucel As Second-Line Therapy in Adult Patients with Aggressive B-cell NHL | Lymphoma, Large B-Cell, Diffuse; Follicular Lymphoma Grade 3B; High-grade B-cell Lymphoma; Mediastin | active not recruiting | 46 |
| 2024-01-22 | P2 | Provention Bio, a Sanofi Company | NCT04270942 At-Risk for Type 1 Diabetes Extension Study (TN-10 Extension) | Diabetes Mellitus, Type 1 | completed | 6 |
| 2024-01-22 | P3 | Arcutis Biotherapeutics, Inc. ARQT | NCT04286607 Open-Label Extension Trial of PDE4 Inhibition With Roflumilast for the Management of Plaque Psoriasis | Chronic Plaque Psoriasis | completed | 337 |
| 2024-01-22 | P3 | China National Biotec Group Company Limited | NCT05091619 A Phase 3 Study of BIBP Diphtheria, Tetanus and Acellular Pertussis (Three Components) Combined Vaccine, Adsorbed | Whooping Cough; Diphtheria; Tetanus | active not recruiting | 2898 |
| 2024-01-22 | P2 | ADC Therapeutics S.A. ADCT | NCT05144009 A Study of Loncastuximab Tesirine and Rituximab (Lonca-R) in Previously Untreated Unfit/Frail Participants With Diffuse Large B-cell Lymphoma (DLBCL) | Diffuse Large B-cell Lymphoma | terminated | 41 |
| 2024-01-22 | P3 | AstraZeneca AZN | NCT05171816 Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer (China Cohort) | Metastatic Castration-resistant Prostate Cancer | active not recruiting | 110 |
| 2024-01-22 | P2 | QOL Medical, LLC | NCT05703009 Effects of Sacrosidase and Placebo in Subjects With Fructan Intolerance | Fructan Intolerance | completed | 25 |
| 2024-01-23 | P2 | Pfizer PFE | NCT04321031 Metabolic Interventions to Resolve Non-alcoholic Steatohepatitis (NASH) With Fibrosis (MIRNA) | Nonalcoholic Fatty Liver Disease; Nonalcoholic Steatohepatitis With Liver Fibrosis | completed | 256 |
| 2024-01-23 | P1/P2 | BioNTech SE BNTX | NCT04382898 PRO-MERIT (Prostate Cancer Messenger RNA Immunotherapy) | Prostate Cancer | terminated | 75 |
| 2024-01-23 | P2 | Gilead Sciences GILD | NCT04891770 Study to Evaluate the Safety and Efficacy of Selgantolimod (SLGN)-Containing Combination Therapies for the Treatment of Chronic Hepatitis B (CHB) | Chronic Hepatitis B | completed | 103 |
| 2024-01-23 | P2 | TiumBio Co., Ltd. | NCT05138562 TUC3PII-01_TU2670 Phase IIa Clinical Study | Endometriosis | completed | 86 |
| 2024-01-23 | P2 | Enterome | NCT05350501 EO2040 in Combination With Nivolumab, for Treatment of Patients With Minimal Residual Disease of Colorectal Cancer | Colorectal Cancer | terminated | 1 |
| 2024-01-23 | P2 | Medesis Pharma SA | NCT05423522 Clinical Safety and Efficacy Evaluation of NanoLithium® NP03 in Patients With Mild-to-severe Alzheimer's Disease | Alzheimer's Disease | completed | 72 |
| 2024-01-23 | P2 | UNION therapeutics UNP | NCT05469464 Study to Assess the Efficacy and Safety of Orismilast in Atopic Dermatitis (ADESOS) | Atopic Dermatitis; Skin Diseases | completed | 235 |
| 2024-01-24 | P2 | Ocular Therapeutix, Inc. OCUL | NCT05335122 A Study to Evaluate the Efficacy and Safety of OTX-TIC (Travoprost) Intracameral Implant for Patients With Open-angle Glaucoma (OAG) or Ocular Hypertension (OHT | Open Angle Glaucoma; Ocular Hypertension | completed | 83 |
| 2024-01-24 | P2 | Ganzhou Hemay Pharmaceutical Co., Ltd | NCT05769946 A Study of Hemay005 in Adult With Atopic Dermatitis | Hemay005, Atopic Dermatitis | completed | 79 |
| 2024-01-24 est. | P1/P2 | Immix Biopharma, Inc. IMMX | NCT05840835 Study of IMX-110 in Combination With Tislelizumab in Patients With Advanced Solid Tumors | Advanced Solid Tumor | unknown | 60 |
| 2024-01-25 | P1/P2 | Bristol-Myers Squibb BMY | NCT02913313 A Study of BMS-986207 Given Alone and in Combination With Nivolumab or With Nivolumab and Ipilimumab in Advanced Solid Tumors | Broad Solid Tumor | completed | 101 |
| 2024-01-25 | P3 | Amgen AMGN | NCT03362177 Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Gastrointestinal, Pancreatic, or Colorectal Cancer | Chemotherapy-induced Thrombocytopenia | completed | 165 |
| 2024-01-25 | P3 | BioTissue Holdings, Inc | NCT04176120 Cryopreserved Human Umbilical Cord (TTAX01) for Late Stage, Complex Non-healing Diabetic Foot Ulcers (AMBULATE DFU) | Diabetic Foot Infection; Non-healing Wound; Non-healing Diabetic Foot Ulcer | completed | 220 |
| 2024-01-25 | P2 | BioNTech SE BNTX | NCT04526899 A Study to Investigate the Novel Agent BNT111 and Cemiplimab in Combination or as Single Agents in Patients With Advanced Melanoma That Has Not Responded to Oth | Melanoma Stage III; Melanoma Stage IV; Unresectable Melanoma | completed | 184 |
| 2024-01-25 | P3 | ACADIA Pharmaceuticals Inc. ACAD | NCT04531982 Efficacy and Safety of Pimavanserin as Adjunctive Treatment for the Negative Symptoms of Schizophrenia | Schizophrenia | completed | 454 |
| 2024-01-25 | P3 | UCB Biopharma SRL | NCT04650854 A Study to Evaluate Rozanolixizumab in Study Participants With Generalized Myasthenia Gravis | Generalized Myasthenia Gravis | completed | 165 |
| 2024-01-25 | P3 | Takeda TAK | NCT04938427 A Study of Soticlestat as an Add-on Therapy in Children, Teenagers, and Adults With Lennox-Gastaut Syndrome | Lennox Gastaut Syndrome (LGS) | completed | 270 |
| 2024-01-25 | P3 | Bayer | NCT05485805 A Study to Learn How Well a Single Dose of the Study Treatment Naproxen Sodium and Caffeine Combined in One Tablet (Fixed-dose Combination) Works to Relieve Pai | Postoperative Dental Pain | completed | 541 |
| 2024-01-26 | P3 | Hoffmann-La Roche | NCT02486718 Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer [IMpower010 | Non-Small Cell Lung Cancer | completed | 1280 |
| 2024-01-26 | P1/P2 | Celgene | NCT03743246 A Study to Evaluate the Safety and Efficacy of JCAR017 in Pediatric Subjects With Relapsed/Refractory (r/r) B-cell Acute Lymphoblastic Leukemia (B-ALL) and B-ce | Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin | terminated | 21 |
| 2024-01-26 | P2 | Imcyse SA | NCT04524949 IMCY-0098 Proof of ACtion in Type 1 Diabetes (IMPACT Study) | Diabetes Mellitus, Type 1 | terminated | 110 |
| 2024-01-26 | P2 | Advaccine (Suzhou) Biopharmaceuticals Co., Ltd. | NCT04681833 Safety and Efficacy of BARS13 in the Elderly | Respiratory Syncytial Virus Infections | completed | 125 |
| 2024-01-26 | P3 | Innovent Biologics (Suzhou) Co. Ltd. | NCT05606913 A Study of IBI362 in Participants With Type 2 Diabetes | Type 2 Diabetes | completed | 731 |
| 2024-01-26 | P2 | Ocumension Therapeutics (Shanghai) Co., Ltd | NCT06435182 Study of OT202 in Treating Moderate to Severe Dry Eye | Dry Eye | completed | 213 |
| 2024-01-29 | P1/P2 | Cardiff Oncology CRDF | NCT03829410 Onvansertib in Combination With FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer Patients With a KRAS Mutation | Metastatic Colorectal Cancer; KRAS Gene Mutation | completed | 68 |
| 2024-01-29 | P3 | GlaxoSmithKline | NCT04484623 Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma | Multiple Myeloma | active not recruiting | 302 |
| 2024-01-29 | P3 | AbbVie ABBV | NCT04542499 Flexible-Dose, Adjunctive Therapy Trial in Adults With Parkinson's Disease With Motor Fluctuations (TEMPO-3) | Parkinson Disease | completed | 507 |
| 2024-01-29 | P2 | Incyte Corporation INCY | NCT04586244 An Umbrella Study to Determine the Safety and Efficacy of Various Monotherapy or Combination Therapies in Neoadjuvant Urothelial Carcinoma | Urothelial Carcinoma | terminated | 30 |
| 2024-01-29 | P1/P2 | Adagene Inc ADAG | NCT04645069 ADG126, ADG126 in Combination With Anti PD1 Antibody, and ADG126 in Combination With ADG106 in Advanced/Metastatic Solid Tumors | Advanced/Metastatic Solid Tumors | completed | 58 |
| 2024-01-29 | P3 | Hoffmann-La Roche | NCT04963270 A Study To Evaluate Efficacy, Safety, Pharmacokinetics, And Pharmacodynamics Of Satralizumab In Patients With Generalized Myasthenia Gravis | Generalized Myasthenia Gravis | terminated | 188 |
| 2024-01-29 | P3 | Akeso | NCT05499390 AK112 in Advanced Non-Small Cell Lung Cancer | Advanced Non-small-cell Lung Cancer | active not recruiting | 398 |
| 2024-01-29 | P3 | Bayer | NCT05587296 A Study to Learn More About How Well Elinzanetant Works and How Safe it is Compared to Placebo for the Treatment of Hot Flashes Caused by Anti-cancer Therapy in | Vasomotor Symptoms Caused by Adjuvant Endocrine Therapy in Women With, or at High Risk for Developin | active not recruiting | 474 |
| 2024-01-29 | P2 | argenx ARGX | NCT05817669 A Study of the Safety and Effectiveness of Efgartigimod in Patients With Primary Sjögren's Syndrome (pSS) | Primary Sjögren's Syndrome | completed | 34 |
| 2024-01-30 | P1/P2 | Hoffmann-La Roche | NCT03671018 A Study to Evaluate the Safety and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With Polatuzumab Vedotin in B-Cell Non-Hodgkin Lymphoma | B-cell Non-Hodgkin Lymphoma | active not recruiting | 422 |
| 2024-01-30 | P3 | AlloVir | NCT04390113 Study to Evaluate Viralym-M (ALVR105) for the Treatment of Virus-Associated Hemorrhagic Cystitis (HC) | BK Virus Infection; Hemorrhagic Cystitis | terminated | 97 |
| 2024-01-30 | P1/P2 | NextCure, Inc. NXTC | NCT04875806 A Safety and Tolerability Study of NC762 in Subjects With Advanced or Metastatic Solid Tumors | Advanced or Metastatic Solid Tumors; Ovarian Cancer; Non-small Cell Lung Cancer; Breast Cancer | terminated | 40 |
| 2024-01-30 | P2 | NeoTX Therapeutics Ltd. | NCT04880863 NAP in Combination With Docetaxel Following Obinutuzumab Pretreatment in Subjects With Checkpoint Inhibitor Pretreated Advanced or Metastatic NSCLC | Non-small Cell Lung Cancer | completed | 38 |
| 2024-01-30 | P3 | Novo Nordisk A/S NVO | NCT04968184 Efficacy and Safety of KBP-5074 in Uncontrolled Hypertension and Moderate or Severe Chronic Kidney Disease (CKD) | Chronic Kidney Diseases | terminated | 666 |
| 2024-01-30 | P3 | Sanotize Research and Development corp. | NCT05109611 Nitric Oxide Nasal Spray (NONS) as Prevention for Treatment of Individuals at Risk of Exposure to COVID-19 Infection | SARS-CoV-2 Infection | terminated | 1389 |
| 2024-01-30 est. | P2 | Shanghai Henlius Biotech | NCT05127759 The Efficacy and Safety of HLX208 in Metastatic Colorectal Cancer (mCRC) With BRAF V600E Mutation | Metastatic Colorectal Cancer; mCRC | unknown | 25 |
| 2024-01-30 | P2/P3 | AlloVir | NCT05305040 Study of Posoleucel (ALVR105,Viralym-M) for Multi-Virus Prevention in Patients Post-Allogeneic Hematopoietic Cell Transplant | Adenovirus Infection; BK Virus Infection; Cytomegalovirus Infections; Epstein-Barr Virus Infections; | terminated | 451 |
| 2024-01-30 est. | P3 | Serum Institute of India Pvt. Ltd. | NCT05447377 A Study of SII Yellow Fever Vaccine to Compare Safety and Immunogenicity With STAMARIL® In Healthy Infants | Yellow Fever | unknown | 2216 |
| 2024-01-30 | P3 | Santen Pharmaceutical Co., Ltd. | NCT05503901 A Long Term Study of STN1012600 in Subjects With Open Angle Glaucoma or Ocular Hypertension | Open Angle Glaucoma, Ocular Hypertension | completed | 131 |
| 2024-01-30 | P3 | Jiangsu Pacific Meinuoke Bio Pharmaceutical Co Ltd | NCT05679479 Study on the Safety and Efficacy of Meplazumab for Injection in Severe Patients With COVID-19 | COVID-19 | completed | 108 |
| 2024-01-30 | P2 | Shanghai HEP Pharmaceutical Co., Ltd. | NCT05827146 Study of Hepalatide in Chronic Hepatitis D(CHD) Patients | Chronic Hepatitis D Infection | completed | 23 |
| 2024-01-31 est. | P3 | Innocoll | NCT03262688 Safety, Tolerability, PK, and Analgesic Effect of INL-001 in Children Following Open Inguinal Hernia Repair | Inguinal Hernia; Postoperative Pain | unknown | 159 |
| 2024-01-31 | P3 | Jiangsu HengRui Medicine Co., Ltd. | NCT03588091 Neoadjuvant Study of Pyrotinib in Combination With Trastuzumab in Patients With HER2 Positive Breast Cancer | HER2-positive Breast Cancer | completed | 355 |
| 2024-01-31 est. | P1/P2 | Jiangsu vcare pharmaceutical technology co., LTD | NCT04614740 The Phase I/Phase II Clinical Study of VC004 in Patients With Localized Advanced/Metastatic Solid Tumors | Locally Advanced Solid Tumor; Metastatic Solid Tumor | unknown | 115 |
| 2024-01-31 | P1/P2 | AlloVir | NCT04933968 Study of ALVR106 in Patients With Respiratory Viral Infections After Hematopoietic Cell and Solid Organ Transplant | Respiratory Tract Viral Infections; Human Metapneumovirus (hMPV) Infection; Parainfluenza (PIV) Infe | terminated | 17 |
| 2024-01-31 | P2 | Keymed Biosciences Co.Ltd | NCT05131464 The Study of CM310 in Patients With Chronic Rhinosinusitis With Nasal Polyps | Chronic Rhinosinusitis With Nasal Polyps | completed | 46 |
| 2024-01-31 | P3 | AlloVir | NCT05179057 Posoleucel (ALVR105) for the Treatment of Adenovirus Infection in Pediatric and Adult Participants Receiving Standard of Care Following Allogeneic Hematopoietic | Adenovirus Infection | terminated | 57 |
| 2024-01-31 est. | P2 | CANbridge Life Sciences Ltd. | NCT05447195 Phase 2 Study of CAN008 in Subjects With GBM | Newly-diagnosed Glioblastoma | unknown | 117 |
| 2024-01-31 | P3 | Teva Branded Pharmaceutical Products R&D, Inc. | NCT05458011 A Randomized, Double-Blind, Placebo-Controlled Study With an Open-Label Period on Efficacy and Safety of Fremanezumab in Chinese Adults With Migraine | Migraine | completed | 365 |
| 2024-01-31 | P1/P2 | Nerviano Medical Sciences | NCT05630937 Study on Safety and Efficacy of NMS-01940153E in Adult Patients With Unresectable Hepatocellular Carcinoma (HCC) Previously Treated With Systemic Therapy | Unresectable Hepatocellular Carcinoma (HCC) | terminated | 31 |
| 2024-01-31 | P3 | Bayer | NCT05643573 A Study to Learn How Well the Study Treatment Asundexian Works and How Safe it is Compared to Apixaban to Prevent Stroke or Systemic Embolism in People With Irr | Prevention of Stroke or Systemic Embolism; Atrial Fibrillation | terminated | 14830 |
| 2024-01-31 | P2 | Jiangsu HengRui Medicine Co., Ltd. | NCT06614153 Pharmacokinetics,Pharmacodynamics,Efficacy and Safety of HRG2010 in Parkinson's Disease Patients With Motor Fluctuations | Parkinson's Disease | completed | 61 |
Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line
results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are
company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA
(openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score.
Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP
readout_calendar / fda_decisions. Not investment advice.